CSPC Pharmaceutical Group (HK:1093) has released an update.
CSPC Innovation Pharmaceutical Co., Ltd., a subsidiary of CSPC Pharmaceutical Group Limited, has released its unaudited financial results for the first half of 2024, showing a significant decrease in revenue and net profit compared to the previous year. Investors are advised to exercise caution when dealing in the company’s securities. The financial report, prepared according to Chinese accounting standards, indicates notable declines in key financial indicators such as net cash flows from operating activities and return on net assets.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.
